{
    "output": [
        [
            "David Drutz, M.D.",
            "PERSON",
            "Remain",
            "Chairman of Compensation Committee",
            "ORG/REG"
        ],
        [
            "David Drutz, M.D.",
            "PERSON",
            "Is_Member_Of",
            "Board",
            "ORG/REG"
        ],
        [
            "Altimmune, Inc.",
            "COMP",
            "Elect",
            "Mitchel Sayare, Ph.D.",
            "PERSON",
            "Chairman of the Company\u2019s Board of Directors",
            "ORG/REG"
        ],
        [
            "Mitchel Sayare, Ph.D.",
            "PERSON",
            "Join",
            "PharmAthene\u2019s Board of Directors",
            "ORG/REG"
        ],
        [
            "Mitchel Sayare, Ph.D.",
            "PERSON",
            "Lead",
            "ImmunoGen",
            "COMP"
        ],
        [
            "ImmunoGen",
            "COMP",
            "Engage",
            "research and development of antibody-based cancer therapeutics",
            "CONCEPT"
        ],
        [
            "Mitchel Sayare, Ph.D.",
            "PERSON",
            "Responsible",
            "raising over $300 million in venture capital and public equity financing",
            "FIN_INSTRUMENT"
        ],
        [
            "Mitchel Sayare, Ph.D.",
            "PERSON",
            "Sits",
            "on a number of other for-profit and not-for-profit boards in the life sciences",
            "ORG"
        ],
        [
            "Mitchel Sayare, Ph.D.",
            "PERSON",
            "Earn",
            "Ph.D. in biochemistry from the Temple University School of Medicine",
            "EDUCATION"
        ],
        [
            "Altimmune, Inc.",
            "COMP",
            "Focused",
            "on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease",
            "CONCEPT"
        ],
        [
            "Altimmune, Inc.",
            "COMP",
            "Have",
            "two United States government funded, next-generation anthrax vaccine candidates",
            "PRODUCT"
        ],
        [
            "Altimmune, Inc.",
            "COMP",
            "Intend",
            "to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines",
            "CONCEPT"
        ]
    ]
}